Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly CEO, In Shanghai, Predicts Better Patent Protection Will Unleash Scientific Innovation Across China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Calling the start of the new millennium "the century of human medicine," John Lechleiter, Eli Lilly's chief executive officer, predicted that Chinese scientists would help shape the era, but also said that the government needs to advance its intellectual property regime in order to unleash innovation

You may also be interested in...



After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities

For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials

After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities

For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials

Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica

SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China

Related Content

Latest News
UsernamePublicRestriction

Register

SC074591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel